Your browser doesn't support javascript.
loading
In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
Ramsden, Diane; Wu, Jing-Tao; Zerler, Brad; Iqbal, Sajida; Jiang, Jim; Clausen, Valerie; Aluri, Krishna; Gu, Yongli; Dennin, Sean; Kim, Joohwan; Chong, Saeho.
Afiliação
  • Ramsden D; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.) dramsden@alnylam.com.
  • Wu JT; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Zerler B; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Iqbal S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Jiang J; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Clausen V; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Aluri K; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Gu Y; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Dennin S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Kim J; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
  • Chong S; Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts (D.R., J.-T.W., J.J., V.C., K.A., Y.G., S.D., J.K., S.C.); The Medicines Company, Parsippany, New Jersey (B.Z.); and Sanofi, Waltham, Massachusetts (S.I.).
Drug Metab Dispos ; 47(10): 1183-1194, 2019 10.
Article em En | MEDLINE | ID: mdl-31270142
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Acetilgalactosamina / RNA Interferente Pequeno / Indutores das Enzimas do Citocromo P-450 / Inibidores das Enzimas do Citocromo P-450 Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Acetilgalactosamina / RNA Interferente Pequeno / Indutores das Enzimas do Citocromo P-450 / Inibidores das Enzimas do Citocromo P-450 Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Drug Metab Dispos Assunto da revista: FARMACOLOGIA Ano de publicação: 2019 Tipo de documento: Article